Shares of VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.07 and traded as low as $0.70. VBI Vaccines shares last traded at $0.71, with a volume of 389,743 shares.
Analysts Set New Price Targets
Separately, Raymond James decreased their price target on shares of VBI Vaccines from $6.00 to $5.00 and set a "strong-buy" rating for the company in a research note on Tuesday, August 9th.
Get VBI Vaccines alerts:VBI Vaccines Trading Down 3.2 %
The company has a market capitalization of $182.28 million, a P/E ratio of -1.81 and a beta of 1.86. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.29 and a quick ratio of 2.19. The stock's 50 day moving average is $0.91 and its 200-day moving average is $1.07.
VBI Vaccines (NASDAQ:VBIV – Get Rating) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.11). The business had revenue of $0.35 million during the quarter, compared to analysts' expectations of $0.70 million. VBI Vaccines had a negative return on equity of 75.37% and a negative net margin of 15,391.36%. As a group, equities research analysts anticipate that VBI Vaccines Inc. will post -0.37 earnings per share for the current year.Institutional Investors Weigh In On VBI Vaccines
A number of hedge funds and other institutional investors have recently bought and sold shares of VBIV. State Street Corp grew its holdings in VBI Vaccines by 31.1% in the first quarter. State Street Corp now owns 16,216,811 shares of the biopharmaceutical company's stock worth $26,920,000 after purchasing an additional 3,844,698 shares during the period. Millennium Management LLC grew its holdings in VBI Vaccines by 211.7% in the second quarter. Millennium Management LLC now owns 1,780,752 shares of the biopharmaceutical company's stock worth $1,440,000 after purchasing an additional 1,209,393 shares during the period. Renaissance Technologies LLC grew its holdings in shares of VBI Vaccines by 358.7% during the second quarter. Renaissance Technologies LLC now owns 789,500 shares of the biopharmaceutical company's stock valued at $638,000 after buying an additional 617,400 shares during the last quarter. Frontier Wealth Management LLC grew its holdings in shares of VBI Vaccines by 1,571.7% during the first quarter. Frontier Wealth Management LLC now owns 601,800 shares of the biopharmaceutical company's stock valued at $951,000 after buying an additional 565,800 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of VBI Vaccines by 88.9% during the first quarter. Bank of America Corp DE now owns 809,425 shares of the biopharmaceutical company's stock valued at $1,343,000 after buying an additional 380,839 shares during the last quarter. Hedge funds and other institutional investors own 39.96% of the company's stock.
About VBI Vaccines
(Get Rating)
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.
Featured Stories
- Get a free copy of the StockNews.com research report on VBI Vaccines (VBIV)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
- Declining Profits Challenge the CarMax Value Proposition
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.